ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 916.3 USD | +0.19% |
|
+0.53% | +57.70% |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.6
USD
Average target price
870.3
USD
Spread / Average Target
-4.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +57.70% | 823B | |
| -7.15% | 353B | |
| +15.31% | 320B | |
| +7.26% | 295B | |
| +13.62% | 239B | |
| +14.55% | 220B | |
| -0.33% | 219B | |
| +8.02% | 167B | |
| -3.35% | 159B | |
| +2.61% | 123B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Diabetes patients on GLP-1s instead of insulin have lower cancer risk, study shows
